PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34265108-7	2021	The immunological characteristics were similar to DPP4i-associated BP: higher reactivity to LAD-1 and LABD97 than to the full-length BP180.	dpp4i	50-55	ladinin 1	Homo sapiens	92-97
29858976-1	2018	INTRODUCTION: DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice.	dpp4i	32-37	dipeptidyl peptidase 4	Homo sapiens	14-19
31576468-10	2020	RESULTS: E-Cadherin was significantly higher in the DPP4I group than in the control group.	dpp4i	52-57	cadherin 1	Mus musculus	9-19
31576468-12	2020	Positive staining for E-cadherin and occludin varied widely between the control and DPP4I groups.	dpp4i	84-89	cadherin 1	Mus musculus	22-32
31576468-12	2020	Positive staining for E-cadherin and occludin varied widely between the control and DPP4I groups.	dpp4i	84-89	occludin	Mus musculus	37-45
31576468-13	2020	CONCLUSION: Up-regulation of E-cadherin and occludin by DPP4I may be correlated with the anti-inflammatory action of DPP4I.	dpp4i	56-61	cadherin 1	Mus musculus	29-39
31576468-13	2020	CONCLUSION: Up-regulation of E-cadherin and occludin by DPP4I may be correlated with the anti-inflammatory action of DPP4I.	dpp4i	56-61	occludin	Mus musculus	44-52
31576468-13	2020	CONCLUSION: Up-regulation of E-cadherin and occludin by DPP4I may be correlated with the anti-inflammatory action of DPP4I.	dpp4i	117-122	cadherin 1	Mus musculus	29-39
31576468-13	2020	CONCLUSION: Up-regulation of E-cadherin and occludin by DPP4I may be correlated with the anti-inflammatory action of DPP4I.	dpp4i	117-122	occludin	Mus musculus	44-52
23829656-9	2014	GLP-1 RA were associated with a significant reduction in the incidence of MACE in comparisons with placebo and pioglitazone, with a non-significant trend towards reduction in DPP4i-controlled studies.	dpp4i	175-180	glucagon like peptide 1 receptor	Homo sapiens	0-5
29535389-4	2018	Of 605 potentially relevant studies, 7 eligible RCTs comprising 2,082 patients were included.SGLT2i/DPP4i showed a greater reduction in HbA1c (weighted mean difference -0.6%, 95% CI -0.7 to -0.5%), fasting plasma glucose, 2 h postprandial plasma glucose, and body weight compared to PCB/DPP4i.	dpp4i	100-105	pyruvate carboxylase	Homo sapiens	283-286
24004910-2	2013	FINDINGS: We investigated sera of patients with type 2 diabetes mellitus (T2DM) treated with metformin and sulfonylurea, insulin glargine or a DPP-4 inhibitor (DPP4i).	dpp4i	160-165	dipeptidyl peptidase 4	Homo sapiens	143-148
24004910-13	2013	Our results suggest that glargine/metformin and DPP4i/metformin treatment may more effectively reduce active TGF-beta serum levels than the sulfonylurea/metformin treatment.	dpp4i	48-53	transforming growth factor beta 1	Homo sapiens	109-117